AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Cystic Fibrosis

Recent research efforts aimed at curing Cystic Fibrosis.

Last updated
Also available in
Français — Mucoviscidose

Cystic Fibrosis

Overview

Cystic fibrosis (CF) is an inherited, autosomal-recessive disease caused by changes in the CFTR gene. Faulty or missing CFTR protein disrupts salt and water movement across cell surfaces, producing thick secretions that damage the lungs and can affect the pancreas, intestines, liver, sweat glands, and reproductive system. GeneReviews: Cystic Fibrosis (ncbi.nlm.nih.gov)

Modern CF care combines CFTR modulators—drugs that improve the function of certain defective CFTR proteins—with airway-clearance therapy, inhaled mucus-thinning medicines and antibiotics, pancreatic enzymes, nutritional support, and treatment of complications; lung transplantation remains an option for advanced lung disease. Trikafta prescribing information GeneReviews: Cystic Fibrosis In the United States, median predicted survival for people born during 2020–2024 was approximately 65 years, but this is a population estimate rather than an individual prognosis and is lower for people unable to use modulators. 2024 CF Foundation Patient Registry report (accessdata.fda.gov)

Scope of Recent Research (2020–present)

Since 2020, CF cure research has accelerated from laboratory concepts toward early human studies of inhaled gene addition, messenger RNA (mRNA), antisense RNA medicines, and gene editing. The dominant question is no longer whether functional CFTR can help lung cells, but whether it can be delivered safely, repeatedly or durably, and broadly enough to reach the airway cells that sustain lung health—especially for people whose mutations do not respond to modulators. The field has multiple clinical-stage genetic therapies, but no therapy has yet demonstrated a permanent cure of CF in people. CF Foundation genetic-therapy overview 2024 CF Foundation Annual Report (cff.org)

Major Breakthroughs and Emerging Therapies

CFTR modulators and improved protein repair. CFTR modulators remain the major practical breakthrough of the modern era: they can substantially improve outcomes by increasing the activity of a person’s own defective CFTR protein, but they do not repair the DNA mutation and do not work for every genotype. In the United States, Trikafta is indicated from age 2 years for people with at least one F508del variant or certain responsive variants, while the continued unmet need among people without usable CFTR protein is a central driver of genetic-medicine research. Trikafta prescribing information CF Foundation genetic-therapy overview (accessdata.fda.gov)

Gene addition. The leading gene-addition approach is to aerosolize a functional CFTR gene into the lungs. 4D-710 uses an engineered adeno-associated virus (AAV) capsid, called A101, to carry a shortened but functional CFTR construct; in CF airway-cell cultures and nonhuman primates, it produced CFTR expression and functional activity after inhalation. 4D-710 preclinical design study A separate program, BI 3720931, uses an inhaled lentiviral vector developed from work by the UK Cystic Fibrosis Gene Therapy Consortium; lentiviral delivery is of interest because it may provide more lasting gene expression than nonintegrating approaches, although integration-related safety requires close assessment. Lenticlair 1 trial summary (pubmed.ncbi.nlm.nih.gov)

mRNA replacement. Inhaled mRNA therapies package instructions for full-length CFTR protein in lipid nanoparticles (LNPs), allowing airway cells to make CFTR without changing their DNA. The concept is mutation-agnostic but transient, so it may require repeat dosing. Earlier clinical testing of MRT5005 established that aerosolized CFTR mRNA could be tested in people with CF, although the randomized Phase 1/2 study did not show consistent lung-function improvement. MRT5005 Phase 1/2 study Newer programs include Arcturus’s ARCT-032 and ReCode’s RCT2100, which seek to improve lung delivery and repeat-dose performance. ARCT-032 Phase 2 trial RCT2100 Phase 2a trial (pubmed.ncbi.nlm.nih.gov)

RNA correction, gene editing, and cell-based concepts. SPL84 is an inhaled antisense oligonucleotide, a short RNA-like medicine intended to correct abnormal splicing of the specific 3849+10kb C>T CFTR variant rather than replace the whole gene. Patient-derived airway-cell experiments found that SPL84 restored CFTR function and that combination with Trikafta could be additive for relevant genotypes. SPL84 patient-derived airway-cell study Gene editing is further from the clinic but potentially more durable: Prime Medicine and the Cystic Fibrosis Foundation are developing prime-editing strategies for mutation “hotspots” and larger CFTR insertions, while considering LNP delivery to the lung. CF Foundation–Prime Medicine collaboration Stem-cell replacement is also under investigation, but remains preclinical because corrected cells must safely engraft, persist, and repopulate the correct airway niches. CF Foundation genetic-therapy overview (sciencedirect.com)

Clinical Trials and Experimental Approaches

4D Molecular Therapeutics sponsors the ongoing Phase 1/2 AEROW study of inhaled 4D-710 in adults with CF. 4D-710 clinical trial In a company-reported interim analysis of 16 modulator-ineligible or -intolerant participants, the lower selected dose showed dose-dependent airway CFTR RNA expression and reported signals across lung function, lung-clearance index, and respiratory quality of life; these preliminary findings require confirmation in the dose-expansion Phase 2 portion and independent peer-reviewed reporting. 4D-710 interim clinical update (clinicaltrials.gov)

Boehringer Ingelheim’s Lenticlair 1 trial of BI 3720931 is a seamless Phase 1/2 study of a single inhaled lentiviral CFTR gene-addition treatment in adults ineligible for modulators; it begins with open-label dose escalation and then moves to a randomized, placebo-controlled expansion stage. Lenticlair 1 trial summary Arcturus completed a 39-participant Phase 1/1b ARCT-032 study in healthy adults and adults with CF, and its Phase 2 LunairCF study is recruiting adults who are not taking modulators, with safety, FEV₁, respiratory symptoms, and chest imaging among planned outcomes. ARCT-032 Phase 1/1b trial ARCT-032 Phase 2 trial (hra.nhs.uk)

For mutation-specific RNA therapy, SpliSense’s Phase 2a SPL84 study is testing weekly inhaled dosing in adults with the 3849+10kb C>T splicing mutation. SPL84 Phase 2 trial The sponsor reported preliminary improvement in lung function in up to 70% of treated participants, but the result remains an early company report rather than a completed peer-reviewed efficacy dataset. SpliSense Phase 2 update The field has also learned from setbacks: Vertex discontinued inhaled CFTR-mRNA candidate VX-522 after a Phase 2 safety/tolerability study was stopped early because of tolerability issues. VX-522 program status (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers test candidate cures in patient-derived nasal and bronchial airway epithelial cells, often grown at an air–liquid interface so that they form a mucus-producing, ciliated surface resembling the airway lining. These systems can measure CFTR channel activity, mucus movement, and response to a candidate therapy before it reaches patients. 4D-710 preclinical design study SPL84 patient-derived airway-cell study Animal studies, especially nonhuman-primate inhalation studies, are then used to assess which airway cells receive treatment, how much transgene is expressed, biodistribution, and immune safety. 4D-710 preclinical design study (pubmed.ncbi.nlm.nih.gov)

Delivery is the central technical problem. Viral vectors must traverse mucus and avoid neutralizing antibodies; LNPs must survive nebulization, reach target airway cells, and release RNA without excessive inflammation. Recent preclinical work has improved LNP aerosolization and explored peptide ligands that increase mRNA delivery to CF airway epithelia. Shearless LNP aerosolization platform Peptide-targeted mRNA-LNP delivery Clinical studies combine safety monitoring with biomarkers such as FEV₁, lung-clearance index, CFTR RNA or protein in airway samples, imaging, and patient-reported respiratory symptoms. 4D-710 interim clinical update ARCT-032 Phase 2 trial (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The Cystic Fibrosis Foundation is the principal nonprofit driver of cure-oriented CF research in the United States. Its Path to a Cure initiative is a $500 million effort, and the Foundation committed up to $15 million for Prime Medicine’s preclinical prime-editing research. CF Foundation–Prime Medicine collaboration The Foundation reported supporting about half a dozen genetic-therapy programs in clinical trials and 95 projects spanning genetic therapies and rare or nonsense mutations. 2024 CF Foundation Annual Report (cff.org)

Key translational organizations include 4D Molecular Therapeutics, Arcturus Therapeutics, ReCode Therapeutics, SpliSense, Vertex, Prime Medicine, Boehringer Ingelheim, and the UK Cystic Fibrosis Gene Therapy Consortium. 2024 CF Foundation Annual Report Lenticlair 1 trial summary The Foundation’s current Path to a Cure Collaborative Research Grant can provide up to $1 million per year for three years plus indirect costs for work advancing CFTR repair or replacement. CF Foundation academic funding opportunities (cff.org)

Strengths, Limitations, and Challenges

The strongest feature of the current effort is therapeutic diversity: gene addition can be mutation-agnostic, mRNA can provide full-length CFTR without altering DNA, antisense medicines can directly address selected RNA defects, and editing could eventually make permanent corrections. CF Foundation genetic-therapy overview Early 4D-710 data also provide an important proof-of-principle that aerosolized genetic medicines can produce detectable CFTR RNA in human airways. 4D-710 interim clinical update (cff.org)

The limitations are substantial. CF lungs contain thick mucus, chronic infection, inflammation, and altered airway architecture that can limit delivery; gene therapies may trigger immune responses or lose effectiveness with repeat dosing; gene editing must avoid unintended DNA changes; and a lung-only therapy may not fully correct pancreatic, gastrointestinal, reproductive, or other organ disease. CF Foundation genetic-therapy overview GeneReviews: Cystic Fibrosis The VX-522 discontinuation illustrates that apparently promising mRNA concepts can fail because of tolerability, while the small size and early phase of most genetic-therapy trials mean that durability and clinical benefit remain uncertain. VX-522 program status ARCT-032 Phase 2 trial (cff.org)

Outlook and Future Directions

As of August 8, 2026, CF is closer to mutation-independent treatment than at any earlier point, but not yet close enough to claim that a durable, whole-body cure is imminent. The most important milestones are reproducible Phase 2 efficacy and safety data for inhaled gene-addition and mRNA programs, evidence that treatment reaches long-lived airway progenitor cells, safe repeat dosing or sustained expression, and proof that benefits persist beyond short-term lung-function changes. A realistic near-term goal is a mutation-agnostic treatment for CF lung disease; a true cure will likely require solving delivery, durability, safety, and multisystem disease together. 4D-710 clinical trial Lenticlair 1 trial summary CF Foundation genetic-therapy overview (clinicaltrials.gov)

References

Don't see your disease? Request a report